Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Net Cash Flow (2016 - 2024)

Trinity Biotech's Net Cash Flow history spans 16 years, with the latest figure at $2.7 million for Q4 2024.

  • On a quarterly basis, Net Cash Flow rose 213.0% to $2.7 million in Q4 2024 year-over-year; TTM through Dec 2025 was $2.7 million, a 0.0% change, with the full-year FY2025 number at $246000.0, down 85.1% from a year prior.
  • Net Cash Flow hit $2.7 million in Q4 2024 for Trinity Biotech, up from -$2.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TRIB hit a ceiling of $14.8 million in Q4 2020 and a floor of -$8.0 million in Q3 2023.
  • Historically, Net Cash Flow has averaged $1.3 million across 5 years, with a median of $449000.0 in 2021.
  • Biggest five-year swings in Net Cash Flow: soared 523.09% in 2020 and later crashed 772.61% in 2022.
  • Tracing TRIB's Net Cash Flow over 5 years: stood at $14.8 million in 2020, then plummeted by 111.67% to -$1.7 million in 2021, then surged by 59.82% to -$696000.0 in 2022, then plummeted by 237.21% to -$2.3 million in 2023, then soared by 213.0% to $2.7 million in 2024.
  • Business Quant data shows Net Cash Flow for TRIB at $2.7 million in Q4 2024, -$2.3 million in Q4 2023, and -$8.0 million in Q3 2023.